Deutsche Bank analyst Pito Chickering raised the firm’s price target on Edwards Lifesciences to $86 from $64 and keeps a Hold rating on the shares. The company reported a mostly inline Q4 with a guidance that is essentially unchanged as the focus is on Evoque, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
